{"id":60609,"date":"2026-06-04T23:16:00","date_gmt":"2026-06-04T14:16:00","guid":{"rendered":"https:\/\/japanir.jp\/en\/company\/company-4882\/"},"modified":"2026-08-23T12:57:20","modified_gmt":"2026-08-23T03:57:20","slug":"company-4882","status":"publish","type":"company","link":"https:\/\/japanir.jp\/en\/company\/company-4882\/","title":{"rendered":"PERSEUS PROTEOMICS INC"},"content":{"rendered":"","protected":false},"featured_media":0,"template":"","meta":{"Ticker":"4882","DATE":"2026-01-09","longName":"Perseus Proteomics Inc.","company_name_ja":"","fullTimeEmployees":35,"address":"","phone":"","website":"https:\/\/www.ppmx.com","industry":"Drug Manufacturers - General","sector":"Healthcare","regularMarketPrice":230,"financialCurrency":"","marketCap":3392,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":-48.170000000000002,"epsForward":0,"bookValue":0,"totalRevenue":135507000,"OperatingIncome":-744956000,"operatingMargins":-549.75,"NetIncome":-718108000,"profitMargins":-529.94000000000005,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":-58.969999999999999,"recommendationMean":0,"recommendationKey":"none","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"{\"success\": true, \"fetched_at\": \"2026-08-01T03:44:56.445930\", \"ticker\": \"4882\", \"ticker_full\": \"4882.T\", \"company_name\": \"PERSEUS PROTEOMICS INC\", \"analyst_recommendations\": {\"has_data\": true, \"recommendation_key\": \"none\", \"recommendation_mean\": null, \"total_analysts\": null, \"strong_buy\": null, \"buy\": null, \"hold\": null, \"sell\": null, \"strong_sell\": null}, \"target_prices\": {\"has_data\": true, \"current\": 145.0, \"high\": null, \"low\": null, \"mean\": null, \"median\": null}, \"earnings_dates\": {\"has_data\": false}, \"shareholders\": {\"has_data\": true, \"insider_pct\": 4.04, \"institution_pct\": 9.66, \"major_holders\": [{\"label\": \"\", \"value\": 4.04}, {\"label\": \"\", \"value\": 9.66}, {\"label\": \"\", \"value\": 10.06}, {\"label\": \"\", \"value\": 4.0}], \"institutional_holders\": [], \"mutualfund_holders\": []}}","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"Perseus Proteomics Inc., a drug discovery biotech venture company, develops and sells antibody-based pharmaceuticals and research reagents for cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. Perseus Proteomics Inc. has a joint research agreement with ASKA Pharmaceutical Co., Ltd. for the development of new antibody drugs and therapeutic drugs for specific disease areas. Perseus Proteomics Inc. was incorporated in 2001 and is headquartered in Tokyo, Japan.","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"financial_data":"","detailed_financial_data":"{\"success\": true, \"fetched_at\": \"2026-08-23T01:51:01.729899\", \"ticker\": \"4882\", \"ticker_full\": \"4882.T\", \"company_name\": \"PERSEUS PROTEOMICS INC\", \"company_info\": {\"name_en\": \"PERSEUS PROTEOMICS INC\", \"long_name\": \"Perseus Proteomics Inc.\", \"sector\": \"Healthcare\", \"industry\": \"Drug Manufacturers - General\", \"website\": \"https:\/\/www.ppmx.com\", \"employees\": 35, \"country\": \"Japan\", \"city\": \"Tokyo\", \"address\": \"30-1 Nihonbashi Hakozakicho\", \"description\": \"Perseus Proteomics Inc., a drug discovery biotech venture company, develops and sells antibody-based pharmaceuticals and research reagents for cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. Perseus Proteomics Inc. has a joint research agreement with ASKA Pharmaceutical Co., Ltd. for the development of new antibody drugs and therapeutic drugs for specific disease areas. Perseus Proteomics Inc. was incorporated in 2001 and is headquartered in Tokyo, Japan.\"}, \"price_trend\": {\"ma_5\": {\"ma_value\": 145.2, \"deviation\": 1.24, \"trend\": \"up\"}, \"ma_25\": {\"ma_value\": 145.12, \"deviation\": 1.3, \"trend\": \"up\"}, \"ma_75\": {\"ma_value\": 156.8, \"deviation\": -6.25, \"trend\": \"down\"}, \"ma_200\": {\"ma_value\": 216.44, \"deviation\": -32.08, \"trend\": \"down\"}}, \"financials\": {\"years\": [{\"year\": 2026, \"revenue\": 135507000.0, \"revenue_fmt\": \"\u00a51\u5104\", \"gross_profit\": 116164000.0, \"gross_profit_fmt\": \"\u00a51\u5104\", \"operating_income\": -744956000.0, \"operating_income_fmt\": \"-\u00a57\u5104\", \"ebit\": -744956000.0, \"ebit_fmt\": \"-\u00a57\u5104\", \"net_income\": -718108000.0, \"net_income_fmt\": \"-\u00a57\u5104\", \"eps\": -48.17, \"operating_margin\": -549.75, \"total_assets\": 1623541000.0, \"total_assets_fmt\": \"\u00a516\u5104\", \"total_equity\": 1217770000.0, \"total_equity_fmt\": \"\u00a512\u5104\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 1515346000.0, \"total_cash_fmt\": \"\u00a515\u5104\", \"equity_ratio\": 75.01, \"de_ratio\": 0.0, \"current_ratio\": 24.58, \"operating_cf\": -653334000.0, \"operating_cf_fmt\": \"-\u00a57\u5104\", \"investing_cf\": -10062000.0, \"investing_cf_fmt\": \"-\u00a510.1M\", \"financing_cf\": 497333000.0, \"financing_cf_fmt\": \"\u00a55\u5104\", \"free_cf\": -663278000.0, \"free_cf_fmt\": \"-\u00a57\u5104\", \"net_margin\": -529.94, \"roe\": -58.97, \"roa\": -44.23}, {\"year\": 2025, \"revenue\": 120375000.0, \"revenue_fmt\": \"\u00a51\u5104\", \"gross_profit\": 104051000.0, \"gross_profit_fmt\": \"\u00a51\u5104\", \"operating_income\": -826430000.0, \"operating_income_fmt\": \"-\u00a58\u5104\", \"ebit\": -826430000.0, \"ebit_fmt\": \"-\u00a58\u5104\", \"net_income\": -904800000.0, \"net_income_fmt\": \"-\u00a59\u5104\", \"eps\": -63.41, \"operating_margin\": -686.55, \"total_assets\": 1818837000.0, \"total_assets_fmt\": \"\u00a518\u5104\", \"total_equity\": 1432407000.0, \"total_equity_fmt\": \"\u00a514\u5104\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 1667921000.0, \"total_cash_fmt\": \"\u00a517\u5104\", \"equity_ratio\": 78.75, \"de_ratio\": 0.0, \"current_ratio\": 14.22, \"operating_cf\": -719485000.0, \"operating_cf_fmt\": \"-\u00a57\u5104\", \"investing_cf\": -75157000.0, \"investing_cf_fmt\": \"-\u00a575.2M\", \"financing_cf\": 923381000.0, \"financing_cf_fmt\": \"\u00a59\u5104\", \"free_cf\": -794642000.0, \"free_cf_fmt\": \"-\u00a58\u5104\", \"net_margin\": -751.65, \"roe\": -63.17, \"roa\": -49.75}, {\"year\": 2024, \"revenue\": 100402000.0, \"revenue_fmt\": \"\u00a51\u5104\", \"gross_profit\": 87685000.0, \"gross_profit_fmt\": \"\u00a587.7M\", \"operating_income\": -894730000.0, \"operating_income_fmt\": \"-\u00a59\u5104\", \"ebit\": -894730000.0, \"ebit_fmt\": \"-\u00a59\u5104\", \"net_income\": -1104460000.0, \"net_income_fmt\": \"-\u00a511\u5104\", \"eps\": -93.69, \"operating_margin\": -891.15, \"total_assets\": 1693810000.0, \"total_assets_fmt\": \"\u00a517\u5104\", \"total_equity\": 1398345000.0, \"total_equity_fmt\": \"\u00a514\u5104\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 1541419000.0, \"total_cash_fmt\": \"\u00a515\u5104\", \"equity_ratio\": 82.56, \"de_ratio\": 0.0, \"current_ratio\": 12.8, \"operating_cf\": -833898000.0, \"operating_cf_fmt\": \"-\u00a58\u5104\", \"investing_cf\": -150343000.0, \"investing_cf_fmt\": \"-\u00a52\u5104\", \"financing_cf\": 63943000.0, \"financing_cf_fmt\": \"\u00a563.9M\", \"free_cf\": -992869000.0, \"free_cf_fmt\": \"-\u00a510\u5104\", \"net_margin\": -1100.04, \"roe\": -78.98, \"roa\": -65.21}, {\"year\": 2023, \"revenue\": 94201000.0, \"revenue_fmt\": \"\u00a594.2M\", \"gross_profit\": 86532000.0, \"gross_profit_fmt\": \"\u00a586.5M\", \"operating_income\": -697770000.0, \"operating_income_fmt\": \"-\u00a57\u5104\", \"ebit\": -697770000.0, \"ebit_fmt\": \"-\u00a57\u5104\", \"net_income\": -786999000.0, \"net_income_fmt\": \"-\u00a58\u5104\", \"eps\": -66.93, \"operating_margin\": -740.72, \"total_assets\": 2566650000.0, \"total_assets_fmt\": \"\u00a526\u5104\", \"total_equity\": 2396545000.0, \"total_equity_fmt\": \"\u00a524\u5104\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 2444934000.0, \"total_cash_fmt\": \"\u00a524\u5104\", \"equity_ratio\": 93.37, \"de_ratio\": 0.0, \"current_ratio\": 22.63, \"operating_cf\": -564274000.0, \"operating_cf_fmt\": \"-\u00a56\u5104\", \"investing_cf\": -212989000.0, \"investing_cf_fmt\": \"-\u00a52\u5104\", \"financing_cf\": -20000.0, \"financing_cf_fmt\": \"-\u00a520,000\", \"free_cf\": -734822000.0, \"free_cf_fmt\": \"-\u00a57\u5104\", \"net_margin\": -835.45, \"roe\": -32.84, \"roa\": -30.66}, {\"year\": 2022, \"revenue\": 0, \"revenue_fmt\": \"N\/A\", \"gross_profit\": 0, \"gross_profit_fmt\": \"N\/A\", \"operating_income\": 0, \"operating_income_fmt\": \"N\/A\", \"ebit\": 0, \"ebit_fmt\": \"N\/A\", \"net_income\": 0, \"net_income_fmt\": \"N\/A\", \"eps\": 0, \"operating_margin\": 0, \"total_assets\": 0, \"total_assets_fmt\": \"N\/A\", \"total_equity\": 0, \"total_equity_fmt\": \"N\/A\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 0, \"total_cash_fmt\": \"N\/A\", \"equity_ratio\": 0, \"de_ratio\": 0, \"current_ratio\": 0, \"operating_cf\": 0, \"operating_cf_fmt\": \"N\/A\", \"investing_cf\": 0, \"investing_cf_fmt\": \"N\/A\", \"financing_cf\": 0, \"financing_cf_fmt\": \"N\/A\", \"free_cf\": 0, \"free_cf_fmt\": \"N\/A\", \"net_margin\": 0, \"roe\": 0, \"roa\": 0}], \"has_data\": true}, \"dividends\": {\"history\": [], \"has_data\": false}}","ma_5_value":0,"ma_5_deviation":0,"ma_5_trend":"","ma_25_value":0,"ma_25_deviation":0,"ma_25_trend":"","ma_75_value":0,"ma_75_deviation":0,"ma_75_trend":"","ma_200_value":0,"ma_200_deviation":0,"ma_200_trend":"","previousClose":0,"open":0,"dayHigh":0,"dayLow":0,"volume":0,"averageVolume":0,"revenueGrowth":0},"sector":[],"class_list":["post-60609","company","type-company","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>PERSEUS PROTEOMICS INC - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4882\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4882\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4882\/\",\"name\":\"PERSEUS PROTEOMICS INC - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-06-04T14:16:00+00:00\",\"dateModified\":\"2026-08-23T03:57:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4882\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4882\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4882\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PERSEUS PROTEOMICS INC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PERSEUS PROTEOMICS INC - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4882\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4882\/","url":"https:\/\/japanir.jp\/en\/company\/company-4882\/","name":"PERSEUS PROTEOMICS INC - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-06-04T14:16:00+00:00","dateModified":"2026-08-23T03:57:20+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4882\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4882\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4882\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"PERSEUS PROTEOMICS INC"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company\/60609","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/company"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=60609"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=60609"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}